Skip to main content
Figure 3 | Breast Cancer Research

Figure 3

From: Changes in insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: a prospective window of opportunity neoadjuvant study

Figure 3

Changes in phosphorylated Akt and phosphorylated extracellular signal-regulated kinase 1/2 levels upon metformin treatment. Allred scores for (A) phosphorylated Akt (p-Akt) S473 and (B) phosphorylated extracellular signal-regulated kinase 1/2 (p-ERK1/2) T202/Y204 as measured pre- and post-metformin treatment. The overall score (average of nuclear and cytoplasmic scores) for p-Akt is shown. (C) and (D) Immunohistochemical staining of tumor tissue for p-Akt S473 (C) and p-ERK1/2 T202/Y204 (D). Representative images are shown for each phospho-protein pre- and post-metformin treatment. Corresponding Allred scores were as follows: p-Akt S473 pre-metformin = 7, post-metformin = 3; p-ERK1/2 T202/Y204 pre-metformin = 8, post-metformin = 0. Scale bar represents 30 μm.

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us